GSK591
Based on 13 publication(s) in Google Scholar
GSK591 (EPZ015866), a chemical probe, is a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) with an IC50 of 4 nM.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 1616391-87-7
- Formula: C22H28N4O2
- Molecular Weight:380.48
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) GSK591
More- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]
- Theranostics. 2021 Jan 27;11(8):3742-3759. [Abstract]
- Cell Rep Med. 2026 Jan 20;7(1):102542. [Abstract]
- Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966. [Abstract]
- J Neurochem. 2024 Feb;168(2):142-160. [Abstract]
- J Biol Chem. 2022 Oct;298(10):102434. [Abstract]
- Exp Cell Res. 2023 Jun 1;427(1):113586. [Abstract]
- Exp Cell Res. 2022 Nov 16;422(1):113413. [Abstract]
- Mol Carcinog. 2023 Aug;62(8):1119-1135. [Abstract]
- bioRxiv. 2023 Apr 3.
- Research Square Print. 26 Oct, 2022
- Research Square Print. 2022 Jul.
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
WB
-
In Vivo Efficacy Study
-
IP
All Histone Methyltransferase Isoforms
More
Biological Activity
|
PRMT5 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 5637 | GI50 |
0.143 μM
Compound: GSK3203591
|
Antiproliferative activity against human 5637 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human 5637 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| 5637 | GI50 |
285 nM
Compound: GSK3203591
|
Antiproliferative activity against human 5637 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human 5637 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| 639-V | GI50 |
342 nM
Compound: GSK3203591
|
Antiproliferative activity against human 639-V cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human 639-V cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| 647-V | GI50 |
62 nM
Compound: GSK3203591
|
Antiproliferative activity against human 647-V cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human 647-V cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| 769-P | GI50 |
203 nM
Compound: GSK3203591
|
Antiproliferative activity against human 769-P cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human 769-P cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| 786-0 | GI50 |
20.3 nM
Compound: GSK3203591
|
Antiproliferative activity against human 786-0 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human 786-0 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| A 172 | GI50 |
0.59 μM
Compound: GSK3203591
|
Antiproliferative activity against human A-172 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human A-172 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| A 172 | GI50 |
29.6 nM
Compound: GSK3203591
|
Antiproliferative activity against human A-172 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human A-172 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| A101D | GI50 |
190 nM
Compound: GSK3203591
|
Antiproliferative activity against human A101D cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human A101D cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| A204 | GI50 |
223 nM
Compound: GSK3203591
|
Antiproliferative activity against human A204 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human A204 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| A-375 | GI50 |
79.6 nM
Compound: GSK3203591
|
Antiproliferative activity against human A-375 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human A-375 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| A-427 | GI50 |
130 nM
Compound: GSK3203591
|
Antiproliferative activity against human A-427 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human A-427 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| A-431 | GI50 |
549 nM
Compound: GSK3203591
|
Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| A498 | GI50 |
50.7 nM
Compound: GSK3203591
|
Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| A549 | GI50 |
80.9 nM
Compound: GSK3203591
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| A673 | GI50 |
119 nM
Compound: GSK3203591
|
Antiproliferative activity against human A673 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human A673 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| ACHN | GI50 |
38.6 nM
Compound: GSK3203591
|
Antiproliferative activity against human ACHN cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human ACHN cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| AGS | GI50 |
2030 nM
Compound: GSK3203591
|
Antiproliferative activity against human AGS cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human AGS cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| AN3-CA | GI50 |
254 nM
Compound: GSK3203591
|
Antiproliferative activity against human AN3-CA cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human AN3-CA cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| ARH-77 | GI50 |
44.4 nM
Compound: GSK3203591
|
Antiproliferative activity against human ARH-77 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human ARH-77 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| ASPC1 | GI50 |
302 nM
Compound: GSK3203591
|
Antiproliferative activity against human ASPC1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human ASPC1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| AU565 | GI50 |
14.6 nM
Compound: GSK3203591
|
Antiproliferative activity against human AU565 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human AU565 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| BE(2)-C | GI50 |
803 nM
Compound: GSK3203591
|
Antiproliferative activity against human BE2C cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human BE2C cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| BeWo | GI50 |
1090 nM
Compound: GSK3203591
|
Antiproliferative activity against human BeWo cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human BeWo cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| BFTC-905 | GI50 |
259 nM
Compound: GSK3203591
|
Antiproliferative activity against human BFTC-905 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human BFTC-905 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| BHT-101 | GI50 |
214 nM
Compound: GSK3203591
|
Antiproliferative activity against human BHT-101 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human BHT-101 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| BJAB | GI50 |
3.1 μM
Compound: GSK3203591
|
Antiproliferative activity against human BJAB cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human BJAB cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| BPH-1 | GI50 |
718 nM
Compound: GSK3203591
|
Antiproliferative activity against human BPH-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human BPH-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| BT-20 | GI50 |
2280 nM
Compound: GSK3203591
|
Antiproliferative activity against human BT-20 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human BT-20 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| BT-474 | GI50 |
172 nM
Compound: GSK3203591
|
Antiproliferative activity against human BT-474 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human BT-474 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| BT-549 | GI50 |
59.4 nM
Compound: GSK3203591
|
Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| BV-173 | GI50 |
10.6 nM
Compound: GSK3203591
|
Antiproliferative activity against human BV-173 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human BV-173 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| BXPC-3 | GI50 |
160 nM
Compound: GSK3203591
|
Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| C32 | GI50 |
14.1 nM
Compound: GSK3203591
|
Antiproliferative activity against human C32 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human C32 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| C-33-A | GI50 |
228 nM
Compound: GSK3203591
|
Antiproliferative activity against human C-33-A cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human C-33-A cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| C-4-II | GI50 |
266 nM
Compound: GSK3203591
|
Antiproliferative activity against human C-4-II cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human C-4-II cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CAKI-1 | GI50 |
68.8 nM
Compound: GSK3203591
|
Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CAKI-2 | GI50 |
114 nM
Compound: GSK3203591
|
Antiproliferative activity against human CAKI-2 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CAKI-2 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CAL-27 | GI50 |
103 nM
Compound: GSK3203591
|
Antiproliferative activity against human CAL-27 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CAL-27 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CAL-62 | GI50 |
253 nM
Compound: GSK3203591
|
Antiproliferative activity against human CAL-62 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CAL-62 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Calu-1 | GI50 |
3050 nM
Compound: GSK3203591
|
Antiproliferative activity against human Calu-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Calu-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Calu-6 | GI50 |
206 nM
Compound: GSK3203591
|
Antiproliferative activity against human Calu-6 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Calu-6 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CAMA-1 | GI50 |
78.9 nM
Compound: GSK3203591
|
Antiproliferative activity against human CAMA-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CAMA-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CAPAN-1 | GI50 |
370 nM
Compound: GSK3203591
|
Antiproliferative activity against human CAPAN-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CAPAN-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Capan-2 | GI50 |
69.7 nM
Compound: GSK3203591
|
Antiproliferative activity against human Capan-2 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Capan-2 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CCF-STTG1 | GI50 |
115 nM
Compound: GSK3203591
|
Antiproliferative activity against human CCF-STTG1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CCF-STTG1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CCRF-CEM | GI50 |
3140 nM
Compound: GSK3203591
|
Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CFPAC-1 | GI50 |
52.3 nM
Compound: GSK3203591
|
Antiproliferative activity against human CFPAC-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CFPAC-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CGTH-W-1 | GI50 |
82.2 nM
Compound: GSK3203591
|
Antiproliferative activity against human CGTH-W-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CGTH-W-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| ChaGo-K-1 | GI50 |
1190 nM
Compound: GSK3203591
|
Antiproliferative activity against human ChaGo-K-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human ChaGo-K-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CHL-1 | GI50 |
247 nM
Compound: GSK3203591
|
Antiproliferative activity against human CHL-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CHL-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CHP-212 | GI50 |
24 nM
Compound: GSK3203591
|
Antiproliferative activity against human CHP-212 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CHP-212 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| COLO 201 | GI50 |
49.6 nM
Compound: GSK3203591
|
Antiproliferative activity against human COLO201 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human COLO201 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| COLO 205 | GI50 |
10000 nM
Compound: GSK3203591
|
Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| COLO 320 | GI50 |
80.3 nM
Compound: GSK3203591
|
Antiproliferative activity against human COLO 320 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human COLO 320 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| COLO 320DM | GI50 |
82.5 nM
Compound: GSK3203591
|
Antiproliferative activity against human Colo 320DM cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Colo 320DM cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| COLO-829 | GI50 |
54.4 nM
Compound: GSK3203591
|
Antiproliferative activity against human COLO-829 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human COLO-829 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| COR-L105 | GI50 |
314 nM
Compound: GSK3203591
|
Antiproliferative activity against human COR-L105 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human COR-L105 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| COR-L23 | GI50 |
147 nM
Compound: GSK3203591
|
Antiproliferative activity against human COR-L23 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human COR-L23 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CRO-AP2 | GI50 |
250 nM
Compound: GSK3203591
|
Antiproliferative activity against human CRO-AP2 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human CRO-AP2 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| CWR22R | GI50 |
2480 nM
Compound: GSK3203591
|
Antiproliferative activity against human 22Rv1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human 22Rv1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| D283 Med | GI50 |
23.5 nM
Compound: GSK3203591
|
Antiproliferative activity against human D283 Med cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human D283 Med cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Daoy | GI50 |
270 nM
Compound: GSK3203591
|
Antiproliferative activity against human Daoy cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Daoy cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Daudi | GI50 |
142 nM
Compound: GSK3203591
|
Antiproliferative activity against human Daudi cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Daudi cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| DB | GI50 |
2.51 nM
Compound: GSK3203591
|
Antiproliferative activity against human DB cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human DB cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| DBTRG-05MG | GI50 |
156 nM
Compound: GSK3203591
|
Antiproliferative activity against human DBTRG-05MG cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human DBTRG-05MG cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Detroit 562 | GI50 |
104 nM
Compound: GSK3203591
|
Antiproliferative activity against human Detroit 562 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Detroit 562 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| DK-MG | GI50 |
89.5 nM
Compound: GSK3203591
|
Antiproliferative activity against human DK-MG cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human DK-MG cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| DLD-1 | GI50 |
134 nM
Compound: GSK3203591
|
Antiproliferative activity against human DLD-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human DLD-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| DMS-114 | GI50 |
1010 nM
Compound: GSK3203591
|
Antiproliferative activity against human DMS-114 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human DMS-114 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| DMS-273 | GI50 |
298 nM
Compound: GSK3203591
|
Antiproliferative activity against human DMS-273 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human DMS-273 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| DMS-53 | GI50 |
106 nM
Compound: GSK3203591
|
Antiproliferative activity against human DMS-53 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human DMS-53 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| DOHH-2 | GI50 |
0.116 μM
Compound: GSK3203591
|
Antiproliferative activity against human DOHH-2 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human DOHH-2 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| DOHH-2 | GI50 |
157 nM
Compound: GSK3203591
|
Antiproliferative activity against human DOHH-2 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human DOHH-2 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| DoTc2-4510 | GI50 |
95.8 nM
Compound: GSK3203591
|
Antiproliferative activity against human DoTc2-4510 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human DoTc2-4510 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| DU-145 | GI50 |
151 nM
Compound: GSK3203591
|
Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| EB-3 | GI50 |
299 nM
Compound: GSK3203591
|
Antiproliferative activity against human EB-3 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human EB-3 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| EFM-19 | GI50 |
69.5 nM
Compound: GSK3203591
|
Antiproliferative activity against human EFM-19 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human EFM-19 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| EM-2 | GI50 |
94 nM
Compound: GSK3203591
|
Antiproliferative activity against human EM-2 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human EM-2 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| ES-2 | GI50 |
106 nM
Compound: GSK3203591
|
Antiproliferative activity against human ES2 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human ES2 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| FaDu | GI50 |
15.4 nM
Compound: GSK3203591
|
Antiproliferative activity against human FaDu cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human FaDu cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| G-401 | GI50 |
38.4 nM
Compound: GSK3203591
|
Antiproliferative activity against human G-401 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human G-401 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| G-402 | GI50 |
99.7 nM
Compound: GSK3203591
|
Antiproliferative activity against human G-402 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human G-402 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| H4 | GI50 |
151 nM
Compound: GSK3203591
|
Antiproliferative activity against human H4 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human H4 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HCC1143 | GI50 |
0.509 μM
Compound: GSK3203591
|
Antiproliferative activity against human HCC1143 cells assessed as cell growth inhibition viability incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human HCC1143 cells assessed as cell growth inhibition viability incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| HCC1806 | GI50 |
0.261 μM
Compound: GSK3203591
|
Antiproliferative activity against human HCC1806 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human HCC1806 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| HCC70 | GI50 |
0.522 μM
Compound: GSK3203591
|
Antiproliferative activity against human HCC70 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human HCC70 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| HCT-116 | GI50 |
166 nM
Compound: GSK3203591
|
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HCT-15 | GI50 |
68.4 nM
Compound: GSK3203591
|
Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HCT-8 | GI50 |
430 nM
Compound: GSK3203591
|
Antiproliferative activity against human HCT-8 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HCT-8 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HEC-1-A | GI50 |
2440 nM
Compound: GSK3203591
|
Antiproliferative activity against human HEC-1-A cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HEC-1-A cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HEL 92.1.7 | GI50 |
9.02 nM
Compound: GSK3203591
|
Antiproliferative activity against human HEL 92.1.7 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HEL 92.1.7 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HeLa | GI50 |
230 nM
Compound: GSK3203591
|
Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HepG2 | GI50 |
214 nM
Compound: GSK3203591
|
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HLE | GI50 |
174 nM
Compound: GSK3203591
|
Antiproliferative activity against human HLE cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HLE cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HOS | GI50 |
223 nM
Compound: GSK3203591
|
Antiproliferative activity against human HOS cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HOS cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HPAF-II | GI50 |
154 nM
Compound: GSK3203591
|
Antiproliferative activity against human HPAF-II cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HPAF-II cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Hs 294T | GI50 |
12.3 nM
Compound: GSK3203591
|
Antiproliferative activity against human Hs294T cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Hs294T cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Hs 695T | GI50 |
602 nM
Compound: GSK3203591
|
Antiproliferative activity against human Hs 695T cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Hs 695T cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Hs 766 | GI50 |
1120 nM
Compound: GSK3203591
|
Antiproliferative activity against human Hs766T cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Hs766T cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Hs-578T | GI50 |
947 nM
Compound: GSK3203591
|
Antiproliferative activity against human Hs-578T cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Hs-578T cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Hs746T | GI50 |
171 nM
Compound: GSK3203591
|
Antiproliferative activity against human Hs746T cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Hs746T cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HT | GI50 |
206 nM
Compound: GSK3203591
|
Antiproliferative activity against human HT cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HT cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HT-1080 | GI50 |
53.5 nM
Compound: GSK3203591
|
Antiproliferative activity against human HT-1080 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HT-1080 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HT1197 | GI50 |
98.9 nM
Compound: GSK3203591
|
Antiproliferative activity against human HT1197 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HT1197 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HT-1376 | GI50 |
13.13 μM
Compound: GSK3203591
|
Antiproliferative activity against human HT-1376 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human HT-1376 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| HT-1376 | GI50 |
297 nM
Compound: GSK3203591
|
Antiproliferative activity against human HT-1376 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HT-1376 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HT-29 | GI50 |
95.2 nM
Compound: GSK3203591
|
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HT-3 | GI50 |
10000 nM
Compound: GSK3203591
|
Antiproliferative activity against human HT-3 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HT-3 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HuCCT-1 | GI50 |
225 nM
Compound: GSK3203591
|
Antiproliferative activity against human HuCCT-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HuCCT-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HUH-6-clone5 | GI50 |
361 nM
Compound: GSK3203591
|
Antiproliferative activity against human HUH-6-clone5 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HUH-6-clone5 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| HuP-T4 | GI50 |
84.9 nM
Compound: GSK3203591
|
Antiproliferative activity against human HuP-T4 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human HuP-T4 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| J82 | GI50 |
20.947 μM
Compound: GSK3203591
|
Antiproliferative activity against human J82 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human J82 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| J82 | GI50 |
83.1 nM
Compound: GSK3203591
|
Antiproliferative activity against human J82 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human J82 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| JAR | GI50 |
485 nM
Compound: GSK3203591
|
Antiproliferative activity against human JAR cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human JAR cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| JEG-3 | GI50 |
216 nM
Compound: GSK3203591
|
Antiproliferative activity against human JEG-3 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human JEG-3 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| JeKo-1 | GI50 |
6.191 μM
Compound: GSK3203591
|
Antiproliferative activity against human JeKo-1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human JeKo-1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| JM1 | GI50 |
0.076 μM
Compound: GSK3203591
|
Antiproliferative activity against human JM1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human JM1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| J-RT3-T3-5 | GI50 |
43.2 nM
Compound: GSK3203591
|
Antiproliferative activity against human J-RT3-T3-5 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human J-RT3-T3-5 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Jurkat | GI50 |
130 nM
Compound: GSK3203591
|
Antiproliferative activity against human Jurkat cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Jurkat cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| JVM-2 | GI50 |
0.172 μM
Compound: GSK3203591
|
Antiproliferative activity against human JVM-2 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human JVM-2 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| K562 | GI50 |
146 nM
Compound: GSK3203591
|
Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| KLE | GI50 |
10000 nM
Compound: GSK3203591
|
Antiproliferative activity against human KLE cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human KLE cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| KMS-11 | GI50 |
0.047 μM
Compound: GSK3203591
|
Antiproliferative activity against human KMS-11 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human KMS-11 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| L-428 | GI50 |
330 nM
Compound: GSK3203591
|
Antiproliferative activity against human L-428 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human L-428 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| LN-229 | GI50 |
1.15 μM
Compound: GSK3203591
|
Antiproliferative activity against human LN-229 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human LN-229 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| LNCaP | GI50 |
2930 nM
Compound: GSK3203591
|
Antiproliferative activity against human LNCaP cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human LNCaP cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| LP-1 | GI50 |
0.975 μM
Compound: GSK3203591
|
Antiproliferative activity against human LP-1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human LP-1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| LS-1034 | GI50 |
172 nM
Compound: GSK3203591
|
Antiproliferative activity against human LS1034 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human LS1034 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| LS174T | GI50 |
170 nM
Compound: GSK3203591
|
Antiproliferative activity against human LS174T cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human LS174T cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Malme-3M | GI50 |
265 nM
Compound: GSK3203591
|
Antiproliferative activity against human Malme-3M cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Malme-3M cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Maver1 | GI50 |
0.133 μM
Compound: GSK3203591
|
Antiproliferative activity against human MAVER-1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human MAVER-1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| MCF7 | GI50 |
0.215 μM
Compound: GSK3203591
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| MCF7 | GI50 |
10.9 nM
Compound: GSK3203591
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MC-IXC | GI50 |
615 nM
Compound: GSK3203591
|
Antiproliferative activity against human MC-IXC cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MC-IXC cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MDA-MB-231 | GI50 |
2.928 μM
Compound: GSK3203591
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| MDA-MB-231 | GI50 |
56.7 nM
Compound: GSK3203591
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MDA-MB-436 | GI50 |
49.7 nM
Compound: GSK3203591
|
Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MDA-MB-453 | GI50 |
0.343 μM
Compound: GSK3203591
|
Antiproliferative activity against human MDA-MB-453 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human MDA-MB-453 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| MDA-MB-453 | GI50 |
64.5 nM
Compound: GSK3203591
|
Antiproliferative activity against human MDA-MB-453 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MDA-MB-453 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MDA-MB-468 | GI50 |
0.585 μM
Compound: GSK3203591
|
Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| MDA-MB-468 | GI50 |
4.83 nM
Compound: GSK3203591
|
Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MEG-01 | GI50 |
10000 nM
Compound: GSK3203591
|
Antiproliferative activity against human MEG-01 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MEG-01 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MES-SA | GI50 |
72 nM
Compound: GSK3203591
|
Antiproliferative activity against human MES-SA cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MES-SA cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MeWo | GI50 |
249 nM
Compound: GSK3203591
|
Antiproliferative activity against human MeWo cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MeWo cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MG-63 | GI50 |
96 nM
Compound: GSK3203591
|
Antiproliferative activity against human MG-63 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MG-63 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MHH-PREB-1 | GI50 |
10000 nM
Compound: GSK3203591
|
Antiproliferative activity against human MHH-PREB-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MHH-PREB-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MIA PaCa-2 | GI50 |
158 nM
Compound: GSK3203591
|
Antiproliferative activity against human MIA PaCa-2 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MIA PaCa-2 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MOLT-16 | GI50 |
54.2 nM
Compound: GSK3203591
|
Antiproliferative activity against human MOLT-16 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MOLT-16 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MOLT-3 | GI50 |
217 nM
Compound: GSK3203591
|
Antiproliferative activity against human MOLT-3 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MOLT-3 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MV4-11 | GI50 |
65.8 nM
Compound: GSK3203591
|
Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| MX1 | GI50 |
294 nM
Compound: GSK3203591
|
Antiproliferative activity against human MX1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human MX1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NALM-6 | GI50 |
110 nM
Compound: GSK3203591
|
Antiproliferative activity against human NALM-6 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human NALM-6 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NCI-H292 | GI50 |
166 nM
Compound: GSK3203591
|
Antiproliferative activity against human NCI-H292 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human NCI-H292 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NCI-H295R | GI50 |
10000 nM
Compound: GSK3203591
|
Antiproliferative activity against human NCI-H295R cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human NCI-H295R cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NCI-H441 | GI50 |
556 nM
Compound: GSK3203591
|
Antiproliferative activity against human NCI-H441 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human NCI-H441 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NCI-H446 | GI50 |
570 nM
Compound: GSK3203591
|
Antiproliferative activity against human NCI-H446 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human NCI-H446 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NCI-H460 | GI50 |
224 nM
Compound: GSK3203591
|
Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NCI-H508 | GI50 |
307 nM
Compound: GSK3203591
|
Antiproliferative activity against human NCI-H508 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human NCI-H508 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NCI-H520 | GI50 |
15.6 nM
Compound: GSK3203591
|
Antiproliferative activity against human NCI-H520 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human NCI-H520 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NCI-H526 | GI50 |
0.138 μM
Compound: GSK3203591
|
Antiproliferative activity against human NCI-H526 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human NCI-H526 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| NCI-H596 | GI50 |
188 nM
Compound: GSK3203591
|
Antiproliferative activity against human NCI-H596 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human NCI-H596 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NCI-H661 | GI50 |
152 nM
Compound: GSK3203591
|
Antiproliferative activity against human NCI-H661 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human NCI-H661 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NCI-H69 | GI50 |
144 nM
Compound: GSK3203591
|
Antiproliferative activity against human NCI-H69 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human NCI-H69 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NCI-H747 | GI50 |
2580 nM
Compound: GSK3203591
|
Antiproliferative activity against human NCI-H747 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human NCI-H747 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| NU-DHL-1 | GI50 |
0.101 μM
Compound: GSK3203591
|
Antiproliferative activity against human NU-DHL-1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human NU-DHL-1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| OE19 | GI50 |
98 nM
Compound: GSK3203591
|
Antiproliferative activity against human OE19 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human OE19 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| OE33 | GI50 |
231 nM
Compound: GSK3203591
|
Antiproliferative activity against human OE33 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human OE33 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| OVCAR-3 | GI50 |
51.4 nM
Compound: GSK3203591
|
Antiproliferative activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| PANC-1 | GI50 |
165 nM
Compound: GSK3203591
|
Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| PC-3 | GI50 |
873 nM
Compound: GSK3203591
|
Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Pfeiffer | GI50 |
0.352 μM
Compound: GSK3203591
|
Antiproliferative activity against human Pfeiffer cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human Pfeiffer cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| Raji | GI50 |
24.5 nM
Compound: GSK3203591
|
Antiproliferative activity against human Raji cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Raji cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Ramos | GI50 |
546 nM
Compound: GSK3203591
|
Antiproliferative activity against human Ramos cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Ramos cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| RCK8 | GI50 |
2.11 μM
Compound: GSK3203591
|
Antiproliferative activity against human RCK8 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human RCK8 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| RD | GI50 |
639 nM
Compound: GSK3203591
|
Antiproliferative activity against human RD cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human RD cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Rec1 | GI50 |
1.994 μM
Compound: GSK3203591
|
Antiproliferative activity against human REC1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human REC1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| RKO | GI50 |
772 nM
Compound: GSK3203591
|
Antiproliferative activity against human RKO cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human RKO cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| RL | GI50 |
1.434 μM
Compound: GSK3203591
|
Antiproliferative activity against human RL cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human RL cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| RL95-2 | GI50 |
218 nM
Compound: GSK3203591
|
Antiproliferative activity against human RL95-2 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human RL95-2 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| RPMI-6666 | GI50 |
748 nM
Compound: GSK3203591
|
Antiproliferative activity against human RPMI-6666 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human RPMI-6666 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| RPMI-7951 | GI50 |
44.2 nM
Compound: GSK3203591
|
Antiproliferative activity against human RPMI-7951 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human RPMI-7951 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| RPMI-8226 | GI50 |
58.4 nM
Compound: GSK3203591
|
Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SAOS-2 | GI50 |
48.2 nM
Compound: GSK3203591
|
Antiproliferative activity against human SAOS-2 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SAOS-2 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SCaBER | GI50 |
0.255 μM
Compound: GSK3203591
|
Antiproliferative activity against human SCaBER cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human SCaBER cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| SCaBER | GI50 |
123 nM
Compound: GSK3203591
|
Antiproliferative activity against human SCaBER cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SCaBER cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SCC-25 | GI50 |
273 nM
Compound: GSK3203591
|
Antiproliferative activity against human SCC-25 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SCC-25 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SCC-4 | GI50 |
286 nM
Compound: GSK3203591
|
Antiproliferative activity against human SCC-4 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SCC-4 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SCC-9 | GI50 |
747 nM
Compound: GSK3203591
|
Antiproliferative activity against human SCC-9 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SCC-9 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SF-295 | GI50 |
9.843 μM
Compound: GSK3203591
|
Antiproliferative activity against human SF-295 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human SF-295 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| SF-539 | GI50 |
0.075 μM
Compound: GSK3203591
|
Antiproliferative activity against human SF-539 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human SF-539 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| SH-4 | GI50 |
75.2 nM
Compound: GSK3203591
|
Antiproliferative activity against human SH-4 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SH-4 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SHP77 | GI50 |
152 nM
Compound: GSK3203591
|
Antiproliferative activity against human SHP77 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SHP77 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SiHa | GI50 |
2510 nM
Compound: GSK3203591
|
Antiproliferative activity against human SiHa cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SiHa cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SJRH30 | GI50 |
472 nM
Compound: GSK3203591
|
Antiproliferative activity against human SJRH30 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SJRH30 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SJSA-1 | GI50 |
773 nM
Compound: GSK3203591
|
Antiproliferative activity against human SJSA-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SJSA-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SK-BR-3 | GI50 |
0.131 μM
Compound: GSK3203591
|
Antiproliferative activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| SK-BR-3 | GI50 |
76.4 nM
Compound: GSK3203591
|
Antiproliferative activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SK-LMS-1 | GI50 |
113 nM
Compound: GSK3203591
|
Antiproliferative activity against human SK-LMS-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SK-LMS-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SK-MEL-1 | GI50 |
38.7 nM
Compound: GSK3203591
|
Antiproliferative activity against human SK-MEL-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SK-MEL-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SK-MEL-28 | GI50 |
239 nM
Compound: GSK3203591
|
Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SK-MEL3 | GI50 |
181 nM
Compound: GSK3203591
|
Antiproliferative activity against human SK-MEL3 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SK-MEL3 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SK-MES-1 | GI50 |
807 nM
Compound: GSK3203591
|
Antiproliferative activity against human SK-MES-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SK-MES-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SK-N-AS | GI50 |
31.9 nM
Compound: GSK3203591
|
Antiproliferative activity against human SK-N-AS cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SK-N-AS cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SK-N-DZ | GI50 |
257 nM
Compound: GSK3203591
|
Antiproliferative activity against human SK-N-DZ cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SK-N-DZ cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SK-NEP-1 | GI50 |
264 nM
Compound: GSK3203591
|
Antiproliferative activity against human SK-NEP-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SK-NEP-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SK-N-FI | GI50 |
308 nM
Compound: GSK3203591
|
Antiproliferative activity against human SK-N-FI cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SK-N-FI cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SK-OV-3 | GI50 |
52.6 nM
Compound: GSK3203591
|
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SK-UT-1 | GI50 |
42.1 nM
Compound: GSK3203591
|
Antiproliferative activity against human SK-UT-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SK-UT-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SNB-19 | GI50 |
223 nM
Compound: GSK3203591
|
Antiproliferative activity against human SNB-19 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SNB-19 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SNU1 | GI50 |
1040 nM
Compound: GSK3203591
|
Antiproliferative activity against human SNU1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SNU1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SNU-16 | GI50 |
34.4 nM
Compound: GSK3203591
|
Antiproliferative activity against human SNU-16 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SNU-16 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SNU-423 | GI50 |
66 nM
Compound: GSK3203591
|
Antiproliferative activity against human SNU-423 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SNU-423 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SNU-5 | GI50 |
110 nM
Compound: GSK3203591
|
Antiproliferative activity against human SNU-5 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SNU-5 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SR | GI50 |
275 nM
Compound: GSK3203591
|
Antiproliferative activity against human SR cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SR cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| ST486 | GI50 |
101 nM
Compound: GSK3203591
|
Antiproliferative activity against human ST486 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human ST486 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SU.86.86 | GI50 |
934 nM
Compound: GSK3203591
|
Antiproliferative activity against human SU-86-86 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SU-86-86 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SUD4 | GI50 |
0.571 μM
Compound: GSK3203591
|
Antiproliferative activity against human SU-DHL-4 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human SU-DHL-4 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| SU-DHL10 | GI50 |
0.495 μM
Compound: GSK3203591
|
Antiproliferative activity against human SU-DHL-10 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human SU-DHL-10 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| SU-DHL-16 | GI50 |
0.124 μM
Compound: GSK3203591
|
Antiproliferative activity against human SU-DHL-16 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human SU-DHL-16 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| SU-DHL-2 | GI50 |
0.086 μM
Compound: GSK3203591
|
Antiproliferative activity against human SUDHL2 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human SUDHL2 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| SU-DHL-5 | GI50 |
0.132 μM
Compound: GSK3203591
|
Antiproliferative activity against human SU-DHL-5 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human SU-DHL-5 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| SU-DHL-6 | GI50 |
0.013 μM
Compound: GSK3203591
|
Antiproliferative activity against human SU-DHL-6 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human SU-DHL-6 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| SU-DHL-8 | GI50 |
1.22 μM
Compound: GSK3203591
|
Antiproliferative activity against human SU-DHL-8 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human SU-DHL-8 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| SW 954 | GI50 |
10000 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW 954 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW 954 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW 962 | GI50 |
203 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW 962 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW 962 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW1088 | GI50 |
40.5 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW1088 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW1088 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW13 | GI50 |
211 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW13 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW13 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW1353 | GI50 |
129 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW1353 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW1353 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW1417 | GI50 |
773 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW1417 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW1417 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW1463 | GI50 |
770 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW1463 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW1463 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW1783 | GI50 |
389 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW1783 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW1783 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW48 | GI50 |
10000 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW48 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW48 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW480 | GI50 |
413 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW480 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW480 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW-620 | GI50 |
5640 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW620 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW620 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW684 | GI50 |
1170 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW684 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW684 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW780 | GI50 |
0.451 μM
Compound: GSK3203591
|
Antiproliferative activity against human SW780 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human SW780 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| SW837 | GI50 |
102 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW837 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW837 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW872 | GI50 |
54 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW872 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW872 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW900 | GI50 |
3250 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW900 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW900 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW948 | GI50 |
120 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW948 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW948 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| SW982 | GI50 |
56.7 nM
Compound: GSK3203591
|
Antiproliferative activity against human SW982 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human SW982 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| T-24 | GI50 |
0.65 μM
Compound: GSK3203591
|
Antiproliferative activity against human T24 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human T24 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| T-24 | GI50 |
449 nM
Compound: GSK3203591
|
Antiproliferative activity against human T24 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human T24 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| T47D | GI50 |
52.4 nM
Compound: GSK3203591
|
Antiproliferative activity against human T47D cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human T47D cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| T98G | GI50 |
27.3 nM
Compound: GSK3203591
|
Antiproliferative activity against human T98G cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human T98G cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| TCC-SUP | GI50 |
235 nM
Compound: GSK3203591
|
Antiproliferative activity against human TCC-SUP cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human TCC-SUP cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| THP-1 | GI50 |
80.5 nM
Compound: GSK3203591
|
Antiproliferative activity against human THP-1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human THP-1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| U138-MG | GI50 |
43.3 nM
Compound: GSK3203591
|
Antiproliferative activity against human U138-MG cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human U138-MG cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| U-251 | GI50 |
3.491 μM
Compound: GSK3203591
|
Antiproliferative activity against human U-251MG cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human U-251MG cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| U-266 | GI50 |
78.5 nM
Compound: GSK3203591
|
Antiproliferative activity against human U266B1 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human U266B1 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| U2932 | GI50 |
0.336 μM
Compound: GSK3203591
|
Antiproliferative activity against human U2932 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human U2932 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| U-2940 | GI50 |
2.349 μM
Compound: GSK3203591
|
Antiproliferative activity against human U-2940 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human U-2940 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| U2OS | GI50 |
485 nM
Compound: GSK3203591
|
Antiproliferative activity against human U2OS cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human U2OS cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| U-87MG ATCC | GI50 |
0.127 μM
Compound: GSK3203591
|
Antiproliferative activity against human U-87 MG cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human U-87 MG cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| U-87MG ATCC | GI50 |
67.6 nM
Compound: GSK3203591
|
Antiproliferative activity against human U-87 MG cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human U-87 MG cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| U-937 | GI50 |
0.049 μM
Compound: GSK3203591
|
Antiproliferative activity against human U-937 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human U-937 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| UMUC3 | GI50 |
105 nM
Compound: GSK3203591
|
Antiproliferative activity against human UMUC3 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human UMUC3 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| UMUC3 | GI50 |
19.169 μM
Compound: GSK3203591
|
Antiproliferative activity against human UMUC3 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human UMUC3 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| WI-38 | GI50 |
18.5 nM
Compound: GSK3203591
|
Antiproliferative activity against human WI-38 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human WI-38 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| WiDr | GI50 |
505 nM
Compound: GSK3203591
|
Antiproliferative activity against human WiDr cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human WiDr cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| WSUDLCL2 | GI50 |
0.651 μM
Compound: GSK3203591
|
Antiproliferative activity against human WSUDLCL2 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human WSUDLCL2 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| WSU-NHL | GI50 |
0.076 μM
Compound: GSK3203591
|
Antiproliferative activity against human WSU-NHL cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human WSU-NHL cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| Y79 | GI50 |
113 nM
Compound: GSK3203591
|
Antiproliferative activity against human Y79 cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human Y79 cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| YAPC | GI50 |
168 nM
Compound: GSK3203591
|
Antiproliferative activity against human YAPC cells assessed as cell growth inhibition incubated for 10 days
Antiproliferative activity against human YAPC cells assessed as cell growth inhibition incubated for 10 days
|
[PMID: 29946150] |
| Z-138 | GI50 |
0.014 μM
Compound: GSK3203591
|
Antiproliferative activity against human Z138 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human Z138 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
| Z-138 | IC50 |
62 nM
Compound: EPZ015866; GSK3203591
|
Antiproliferative activity against human Z138 cells incubated for 5 days by cell titer-glo assay
Antiproliferative activity against human Z138 cells incubated for 5 days by cell titer-glo assay
|
[PMID: 26985292] |
| ZR-75-1 | GI50 |
2.615 μM
Compound: GSK3203591
|
Antiproliferative activity against human ZR-75-1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
Antiproliferative activity against human ZR-75-1 cells assessed as cell growth inhibition incubated for 6 days by celltiter-glo assay
|
[PMID: 29946150] |
GSK591 (5 μM; MCF7, T47D, and MCF10A cells) treatment suppresses breast cancer stem cells (BCSCs) proliferation and self-renewal. GSK591 reduces BCSCs numbers in vitro[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF7, T47D, and MCF10A cells
-
Concentration:5 μM
-
Incubation Time:
-
Result:Suppressed BCSCs proliferation and self-renewal.
Chemical Information
-
CAS No. 1616391-87-7
-
Appearance Solid
-
Molecular Weight 380.48
-
Formula C22H28N4O2
-
Color White to off-white
-
SMILES
O=C(C1=CC(NC2CCC2)=NC=C1)NC[C@H](O)CN3CC4=C(C=CC=C4)CC3
-
Synonyms
EPZ015866; GSK3203591
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Nat Commun
Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. [Abstract]2019 Aug 21;10(1):3761. PMID: 31434880
GSK591 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]
ChIP assay analysis of the enrichment of H3R2me1 and H3R2me2s on the promoter of SLC7A11 in the indicated cells treated with PRMT5 inhibitor GSK591 (5 μM, 1 h). ChIP-qPCR of Histone 3 served as the control. The results showed that inhibiting PRMT5 activity using the PRMT5 inhibitor GSK591 significantly reduced the levels of H3R2me1 and H3R2me2s on the SLC7A11 promoter in CPT-treated cells.
-
Theranostics
PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression. [Abstract]2021 Jan 27;11(8):3742-3759. PMID: 33664859
GSK591 purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jan 27;11(8):3742-3759. [Abstract]
The compound dose-response matrix for proliferation inhibition of HCT116 and SW480 cells treated with PRMT5i (GSK591) (10-100 μM; 7 days) and EZH2i (GSK126). Color gradation indicates percentage viability at the indicated dose combination. Combination index (CI) plots for 100 nM PRMT5i (GSK591) (top) or EZH2i (GSK126) (bottom) with graded doses of EZH2i (GSK126) or PRMT5i (GSK591) in HCT116 and SW480 cells.
GSK591 purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jan 27;11(8):3742-3759. [Abstract]
Immunoblots of PRMT5, EZH2 and CDKN2B (p15INK4b) protein levels in HCT116 and SW480 cells following treatment with PRMT5i (GSK591; 100 nM), EZH2i (GSK126; 100 nM), or PRMT5i (GSK591; 100 nM) + EZH2i (GSK126; 100 nM). GAPDH was used as a loading control. Western blot analysis clearly showed that the selected combination of PRMT5i (GSK591) and EZH2i (GSK126) robustly activated the protein expression of CDKN2B.
GSK591 purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jan 27;11(8):3742-3759. [Abstract]
Representative images of xenograft tumors excised from mice. Control, PRMT5i (GSK591) (100 mg/kg; i.p.; every other day for a month), EZH2i (GSK126) (100 mg/kg; i.p.; every other day for a month), or PRMT5i (GSK591) + EZH2i (GSK126)-treated HCT116 cells were subcutaneously injected into the flank of nude mice.
-
Cell Rep Med
2026 Jan 20;7(1):102542. PMID: 41564858 -
Proc Natl Acad Sci U S A
2019 Feb 19;116(8):2961-2966. PMID: 30718431 -
J Neurochem
L-ascorbyl-2-phosphate alleviates white matter injury caused by chronic hypoxia through the PRMT5/P53/NF-κB pathway. [Abstract]2024 Feb;168(2):142-160. PMID: 38169121 -
J Biol Chem
Protein arginine methyltransferase 5 is essential for oncogene product EWSR1-ATF1-mediated gene transcription in clear cell sarcoma. [Abstract]2022 Oct;298(10):102434. PMID: 36041632 -
Exp Cell Res
2023 Jun 1;427(1):113586. PMID: 37030331 -
Exp Cell Res
PRMT6 functionally associates with PRMT5 to promote colorectal cancer progression through epigenetically repressing the expression of CDKN2B and CCNG1. [Abstract]2022 Nov 16;422(1):113413. PMID: 36400182
GSK591 purchased from MedChemExpress. Usage Cited in: Exp Cell Res. 2022 Nov 16;422(1):113413. [Abstract]
GSK591 (PRMT5i; 200-1000 nM) in combination with EPZ020411 (PRMT6i; 200-1000 nM) exhibits a synergistic anti-proliferative effect on HCT116 and SW620 cells.
-
Mol Carcinog
PRMT1 inhibition promotes ferroptosis sensitivity via ACSL1 upregulation in acute myeloid leukemia. [Abstract]2023 Aug;62(8):1119-1135. PMID: 37144835 -
-
-
Solvent & Solubility
DMSO : 50 mg/mL (131.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.25 mg/mL (5.91 mM); Clear solution
This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.25 mg/mL (5.91 mM); Clear solution
This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. [1] Kenneth W. Duncan et al. Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. ACS Med. Chem. Lett., 2016, 7 (2), pp 162-166. [Content Brief]
[2]. Chiang K, et al. PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression. Cell Rep. 2017 Dec 19;21(12):3498-3513. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6283 mL | 13.1413 mL | 26.2826 mL | 65.7065 mL |
| 5 mM | 0.5257 mL | 2.6283 mL | 5.2565 mL | 13.1413 mL | |
| 10 mM | 0.2628 mL | 1.3141 mL | 2.6283 mL | 6.5706 mL | |
| 15 mM | 0.1752 mL | 0.8761 mL | 1.7522 mL | 4.3804 mL | |
| 20 mM | 0.1314 mL | 0.6571 mL | 1.3141 mL | 3.2853 mL | |
| 25 mM | 0.1051 mL | 0.5257 mL | 1.0513 mL | 2.6283 mL | |
| 30 mM | 0.0876 mL | 0.4380 mL | 0.8761 mL | 2.1902 mL | |
| 40 mM | 0.0657 mL | 0.3285 mL | 0.6571 mL | 1.6427 mL | |
| 50 mM | 0.0526 mL | 0.2628 mL | 0.5257 mL | 1.3141 mL | |
| 60 mM | 0.0438 mL | 0.2190 mL | 0.4380 mL | 1.0951 mL | |
| 80 mM | 0.0329 mL | 0.1643 mL | 0.3285 mL | 0.8213 mL | |
| 100 mM | 0.0263 mL | 0.1314 mL | 0.2628 mL | 0.6571 mL |